Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir and Daclatasvir for COVID-19
NCT04443725Phase 3Unknown
- Sponsor
- Cairo University
- Start
- Jul 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Hydroxychloroquine plus Sofosbuvir/Daclatasvir with Standard of care (2 arms). Primary endpoint: Virological cure at 28 days. Status: unknown.
02
Drugs
sofosbuvirdaclatasvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04443725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04443725.